WallStreetZenWallStreetZen

NASDAQ: WINT
Windtree Therapeutics Inc Stock

$4.84-0.14 (-2.81%)
Updated Mar 27, 2023
WINT Price
$4.84
Fair Value Price
$18.53
Market Cap
$3.74M
52 Week Low
$4.28
52 Week High
$71.50
P/E
-0.07x
P/B
0.21x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$42.59M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.76
Operating Cash Flow
-$21M
Beta
0.54
Next Earnings
Mar 29, 2023
Ex-Dividend
N/A
Next Dividend
N/A

WINT Overview

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how WINT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

WINT ($4.84) is undervalued by 73.88% relative to our estimate of its Fair Value price of $18.53 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
WINT ($4.84) is significantly undervalued by 73.88% relative to our estimate of its Fair Value price of $18.53 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
WINT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more WINT due diligence checks available for Premium users.

Be the first to know about important WINT news, forecast changes, insider trades & much more!

WINT News

Valuation

WINT fair value

Fair Value of WINT stock based on Discounted Cash Flow (DCF)
Price
$4.84
Fair Value
$18.53
Undervalued by
73.88%
WINT ($4.84) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
WINT ($4.84) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
WINT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

WINT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.07x
Industry
18.55x
Market
21.44x

WINT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.21x
Industry
4.86x
WINT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

WINT's financial health

Profit margin

Revenue
$0.0
Net Income
-$4.1M
Profit Margin
0%
WINT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$48.1M
Liabilities
$30.7M
Debt to equity
1.76
WINT's short-term assets ($10.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WINT's long-term liabilities ($26.73M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WINT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
WINT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.1M
Investing
$0.0
Financing
$1.2M
WINT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

WINT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
WINT$3.74M-2.81%-0.07x0.21x
QLGN$3.77M-6.96%-0.17x0.31x
VYNT$3.78M-1.54%-0.08x0.27x
ATNF$3.78M-4.10%-0.26x0.15x
AMPE$3.64M-3.60%-0.22x0.31x

Windtree Therapeutics Stock FAQ

What is Windtree Therapeutics's quote symbol?

NASDAQ: WINT) Windtree Therapeutics trades on the NASDAQ under the ticker symbol WINT. Windtree Therapeutics stock quotes can also be displayed as NASDAQ: WINT.

If you're new to stock investing, here's how to buy Windtree Therapeutics stock.

What is the 52 week high and low for Windtree Therapeutics (NASDAQ: WINT)?

(NASDAQ: WINT) Windtree Therapeutics's 52-week high was $71.50, and its 52-week low was $4.28. It is currently -93.23% from its 52-week high and 13.08% from its 52-week low.

How much is Windtree Therapeutics stock worth today?

(NASDAQ: WINT) Windtree Therapeutics currently has 772,202 outstanding shares. With Windtree Therapeutics stock trading at $4.84 per share, the total value of Windtree Therapeutics stock (market capitalization) is $3.74M.

Windtree Therapeutics stock was originally listed at a price of $2,520,000.00 in Dec 31, 1997. If you had invested in Windtree Therapeutics stock at $2,520,000.00, your return over the last 25 years would have been -100%, for an annualized return of -40.93% (not including any dividends or dividend reinvestments).

How much is Windtree Therapeutics's stock price per share?

(NASDAQ: WINT) Windtree Therapeutics stock price per share is $4.84 today (as of Mar 27, 2023).

What is Windtree Therapeutics's Market Cap?

(NASDAQ: WINT) Windtree Therapeutics's market cap is $3.74M, as of Mar 29, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Windtree Therapeutics's market cap is calculated by multiplying WINT's current stock price of $4.84 by WINT's total outstanding shares of 772,202.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.